0 (0%)		11-11 17:45
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	2.65	1-year :	3.21
Resists	First :	2.27	Second :	2.75
Pivot price	2.05
Supports	First :	1.5	Second :	1.25
MAs	MA(5) :	1.92	MA(20) :	1.99
	MA(100) :	2.6	MA(250) :	3.58
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	12.5	D(3) :	18.1
RSI	RSI(14): 44.1
52-week	High :	6.74	Low :	1.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NRBO ] has closed above bottom band by 29.6%. Bollinger Bands are 18.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2 - 2.01	2.01 - 2.02
Low:	1.86 - 1.87	1.87 - 1.88
Close:	1.9 - 1.92	1.92 - 1.93

Sun, 20 Apr 2025
Prediction of multi-task physicochemical indices based on hyperspectral imaging and analysis of the relationship between physicochemical composition and sensory quality of tea - ScienceDirect.com

Tue, 15 Apr 2025
Optimal allocation of hybrid PVDG and DSVC devices into distribution grids using a modified NRBO algorithm considering the overcurrent protection characteristics - Nature

Thu, 03 Apr 2025
An interpretable deep learning model for the accurate prediction of mean fragmentation size in blasting operations - Nature

Tue, 03 Dec 2024
MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024… - Yahoo Finance

Mon, 01 Jul 2024
NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models… - Yahoo Finance

Sat, 22 Jun 2024
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	9 (M)
Shares Float	2 (M)
Held by Insiders	65.2 (%)
Held by Institutions	12.7 (%)
Shares Short	34 (K)
Shares Short P.Month	24 (K)

EPS	-4.29
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-74.4 %
Return on Equity (ttm)	-160.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.35
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.45
PEG Ratio	0
Price to Book value	1.27
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.